Application of mRNA for use as a therapeutic agent for tumorous diseases
AssigneeCureVac AG
InventorsIngmar Hoerr, Florian Von Der Mulbe, Steve Pascolo
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer.
Claims27
A method for preparing a pharmaceutical composition comprising an RNA which codes for an antigen from a tumour comprising:
- (a) preparing a tumour tissue cDNA library from tumour tissue from a patient comprising:
- (i) comparing the sequences of a cDNA library from healthy tissue to the sequences of the cDNA from tumour tissue;
- and
- (ii) identifying cDNA sequences which are present exclusively in the tumour tissue cDNA library and code for tumour-specific antigens of said patient based upon an alignment with the cDNA library from healthy tissue,
- wherein the tumour tissue cDNA library is a subtraction library of the entire cDNA library from healthy tissue;
- (b) preparing a matrix for in vitro transcription of RNA using the tumour tissue cDNA library which is present exclusively in the tumour tissue cDNA library and codes for tumour-specific antigens of the patient;
- (c) transcribing the matrix in vitro;
- and
- (d) formulating the transcribed RNA into a pharmaceutical composition which does not comprise cells;
- wherein the tumour specific antigens are not present in non-tumour tissue.
A method for preparing a pharmaceutical composition comprising at least one tumour-specific RNA which codes for an antigen expressed in a tumour in a patient comprising:
- (a) preparing a cDNA library from a portion of tumour tissue to obtain a tumour cDNA library;
- (b) preparing a cDNA library from a portion of non-tumour tissue to obtain a non-tumour cDNA library;
- (c) comparing the tumour cDNA library with the non-tumour cDNA library;
- (d) identifying cDNA sequences which are present exclusively in the tumour cDNA library and not present in the non-tumour cDNA library to obtain at least one tumour-specific cDNA which corresponds to an mRNA expressed exclusively in the tumour;
- (e) transcribing the at least one tumour-specific cDNA to obtain tumour-specific RNA which codes for tumour-specific antigens of the patient;
- and
- (f) formulating the tumour-specific RNA into a pharmaceutical composition which does not comprise cells;
- wherein the tumour specific antigens are not present in non-tumour tissue.
Dependencies are inferred from the claim text.